Therefore, CHK1 inhibitors could have anti-tumor properties in p53-deficient cancer cells if used in combination with standard chemotherapy and radiation therapy as these agents induced DNA damage and such cells are highly reliant on repair mechanisms during the G2/M phase and intra S phase for their survival 55. This evidence concerns the gene TP53 and cancer.